0001493152-24-014076.txt : 20240409 0001493152-24-014076.hdr.sgml : 20240409 20240409163025 ACCESSION NUMBER: 0001493152-24-014076 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 24833095 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
false 0001642375 0001642375 2024-04-03 2024-04-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 3, 2024

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment to Jan Hall Employment Agreement

 

On April 3, 2024, the Company entered into an amendment (the “Hall Amendment”) with Janet (“Jan”) Hall, our President and Chief Executive Officer, to the existing employment agreement, dated May 28, 2023, between the Company and Ms. Hall (the “Hall Employment Agreement”). The Hall Amendment increases the transaction bonus payable to Ms. Hall in the event of a Change of Control (as defined in the Hall Employment Agreement”) from $200,000 to $300,000, subject to continued employment though the occurrence of the Change of Control, compliance with any restrictive covenants, a release of claims, and, if requested by the Company, agreeing to provide customary transition services to the Company. The Hall Amendment also provides (i) that in the event the Company terminates Ms. Hall’s employment without Cause (as defined in the Hall Employment Agreement) and such Change of Control occurs on or prior to June 30, 2024, the Company shall pay the cost of or provide to Ms. Hall continuation of group health benefits for the severance period, and (ii) that the Company, in its sole discretion, may pay Ms. Hall’s severance in a lump sum to the extent permissible under Section 409A of the Internal Revenue Code (the “Code”); provided, however, in the event Ms. Hall becomes engaged or retained as an employee, consultant, independent contractor, advisor, or otherwise, on a full-time basis by the acquirer or an affiliate of the acquirer in such Change of Control within 90 days of her termination of employment, Ms. Hall will be required to repay the Company her full severance amount, plus any fees or expenses incurred by the Company to collect such severance payments.

 

Amendment to Katie Cox Employment Agreement

 

On April 3, 2024, the Company entered into an amendment (the “Cox Amendment”) with Katie Cox, our Chief Accounting Officer, to the existing employment agreement, dated September 21, 2023, between the Company and Ms. Cox (the “Cox Employment Agreement”). The Cox Amendment (i) provides that in the event the Company terminates Ms. Cox’s employment without Cause (as defined in the Cox Employment Agreement) following a Change in Control (as defined in the Cox Employment Agreement), and the orderly wind-down and liquidation of the Company following such Change in Control, Ms. Cox will be entitled to severance in the form of nine months of her base salary to be paid in one lump sum within sixty days of Ms. Cox’s termination date and continuation of group health benefits; (ii) provides her with a $25,000 transaction bonus in the event such Change of Control closes on or prior to June 30, 2024 and Ms. Cox satisfies certain enumerated conditions such as Ms. Cox’s (a) devoted contribution to a successful completion of the Change of Control, (b) continued employment with the Company, its successor or acquiror through the closing date of the Change of Control and the payment date, (c) compliance with any restrictive covenants set forth in the Cox Employment Agreement or any other written agreement with the Company or its affiliates, and (d) execution and non-revocation of a release of claims, and if requested by the Company, agreeing to provide customary transition services to the Company, and (iii) provides her with a $50,000 retention bonus subject to Ms. Cox’s (a) continued employment with the Company though the closing date of a subsequent Change of Control, (b) continued employment with the Company through the orderly wind-down and liquidation of the Company following such subsequent Change of Control and compliance with any restrictive covenants, a release of claims, and (c) if requested by the Company, agreeing to provide customary transition services to the Company.

 

Amendment to Craig Sheehan Employment Agreement

 

On April 3, 2024, the Company entered into an amendment (the “Sheehan Amendment”) with Craig Sheehan, our Chief Commercial Officer, to the existing employment agreement, dated June 2, 2021, between the Company and Mr. Sheehan (the “Sheehan Employment Agreement”). The Sheehan Employment Amendment (i) provides him with a $35,000 bonus in the event his employment is terminated by the Company without Cause (as defined in the Sheehan Employment Agreement), subject to a Change of Control (as defined in the Sheehan Employment Agreement) that occurs on or prior to June 30, 2024, and (ii) provides that the Company, in its sole discretion, may pay Mr. Sheehan’s severance in a lump sum to the extent permissible under Section 409A of the Code; provided, however, in the event Mr. Sheehan becomes engaged or retained, as an employee, consultant, independent contractor, advisor, or otherwise, on a full-time basis by the acquirer or an affiliate of the acquirer in such Change of Control within 90 days of his termination of employment, Mr. Sheehan will be required to repay the Company his full severance amount, plus any fees or expenses incurred by the Company to collect such severance payments.

 

 
 

 

No Solicitation

 

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction or a solicitation of any vote or approval.

 

Forward-Looking Statements

 

The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, supply chain disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit
10.1   Amendment to Employment Agreement, dated as of April 3, 2024, by and between Guardion Health Sciences, Inc. and Janet Hall
10.2   Amendment to Employment Agreement, dated as of April 3, 2024, by and between Guardion Health Sciences, Inc. and Katie Cox
10.3   Amendment to Employment Agreement, dated as of April 3, 2024, by and between Guardion Health Sciences, Inc. and Craig Sheehan
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
Date: April 9, 2024    
  By: /s/ Jan Hall
  Name: Jan Hall
  Title: President and Chief Executive Officer

 

 

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

AMENDMENT

TO EMPLOYMENT AGREEMENT

 

This Amendment to Employment Agreement (this “Amendment”), dated effective as of the last date of signature noted on the signature page, is entered into by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), Janet Hall (the “Employee” and together with the Company, collectively, the “Parties”).

 

RECITALS

 

WHEREAS, the Employee and the Company are parties to that certain Employment Agreement, effective as of June 19, 2023 (the “Employment Agreement”), pursuant to which, among other things, the Employee serves as the President and Chief Executive Officer; and

 

WHEREAS, the Employee and the Company desire to amend the Employment Agreement to reflect the Parties understanding regarding the Employee’s compensation.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

1. Amendment of Agreement.

 

A. Section 4(b)(i) of the Agreement is hereby amended by increasing the Transaction Bonus from $200,000 to $300,000.

 

B. Section 4(b)(iii)(B) of the Agreement is hereby amended and replaced in its entirety as follows:

 

“(B) The Change of Control must be consummated on or before June 30, 2024.”

 

C. Section 5(c)(iv) of the Agreement is hereby amended to replace item (1) in the first sentence as follows:

 

“(1) nine (9) months’ Base Salary, which will be increased to twelve (12) months’ Base Salary if the Employee’s termination of employment occurs on or after May 17, 2024”

 

1

 

 

D. Section 5(c)(iv) of the Agreement is hereby amended to add the following to the end of the subclause:

 

“In the event that the Company terminates the Term and the Employee’s employment without Cause following a Change in Control that occurs on or before June 30, 2024, the Company shall pay or provide to the Employee, subject to paragraph vii below (other than with respect to Item (2)), and subject to applicable withholdings, for continuation of group health benefits during the period the Employee is entitled to severance (or, at the Board’s discretion, an equivalent amount, as determined by the Board in good faith). In the event a Change in Control is not consummated on or before June 30, 2024, the Employee shall not be entitled to the continuation of group health benefits or to its equivalent. Notwithstanding the foregoing, the Board, in its sole discretion, may pay any severance payable pursuant to the Section 4(c)(iv) or (vi) in a lump sum to the extent permissible under Section 409A of the Code; provided, however, in the event that within 90 days following the termination of the Employee’s employment by the Company without Cause or by the Employee for Good Reason upon or following the consummation of a Change in Control that occurs on or before June 30, 2024, the Employee becomes engaged or retained, as an employee, consultant, independent contractor, advisor, or otherwise, on a full-time basis by acquiror or an affiliate of the acquiror in such Change of Control, the Employee will be required to repay the Company the full severance amount paid to Employee, plus, if Employee fails to timely repay the Company such severance, any fees or expenses incurred by the Company to collect such severance payments. For purposes of the prior sentence, to be engaged or retained on a “full-time basis” shall mean working an average of 40 hours per week.”

 

E. Section 5(c)(vi) of the Agreement is hereby amended to delete the first “(1)” and replace second item (1) in the first sentence as follows:

 

“(1) nine (9) months’ Base Salary, which will be increased to twelve (12) months’ Base Salary if the Employee’s termination of employment occurs on or after May 17, 2024”

 

2. Acknowledgement. The Employee acknowledges and agrees that by executing this Amendment, the Employee expressly consents to the changes to the terms and conditions in the Agreement.

 

3. Agreement Effective. Except as otherwise expressly provided herein, all terms and conditions of the Agreement will remain unmodified and in full force and effect.

 

4. Precedence of Amendment. In the event of a conflict between the terms and conditions of this Amendment and the terms and conditions of the Agreement, the terms and conditions of this Amendment will govern and control.

 

5. Capitalized Terms. All capitalized terms used in this Amendment and not otherwise defined herein will have the meaning ascribed to such terms in the Agreement.

 

6. Incorporation. This Amendment shall be attached to, and made a part of, the Agreement.

 

7. Counterparts. This Amendment may be executed in one or more copies or counterparts, each of which when signed will be an original, but all of which together will constitute one instrument. Signatures submitted via telecopy or electronic signature shall have the same force and effect as original signatures and, as such, shall be valid and binding upon the parties hereto.

 

[signature page follows]

 

2

 

 

In witness whereof, the Parties hereto have executed this Amendment as of the signature dates set forth below, to be effective as of the date hereof.

 

GUARDION HEALTH SCIENCES, INC.,   “EMPLOYEE”
a Delaware corporation      
         
By:     By:  
  Robert N. Weingarten     Janet Hall
         
Date:     Date:  

 

3

 

 EX-10.2 3 ex10-2.htm

 

Exhibit 10.2

 

AMENDMENT

TO EMPLOYMENT AGREEMENT

AND

TERMINATION OF
RETENTION AGREEMENT

 

This Amendment to Employment Agreement (this “Amendment”), dated effective as of the last date of signature noted on the signature page, is entered into by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), Katie Cox (the “Employee” and together with the Company, collectively, the “Parties”).

 

RECITALS

 

WHEREAS, the Employee and the Company are parties to that certain Employment Agreement, effective as of September 21, 2023 (the “Employment Agreement”), pursuant to which, among other things, the Employee serves as the Chief Accounting Officer;

 

WHEREAS, the Parties entered into that certain Retention Agreement, dated May 18, 2023 (the “Retention Agreement”), pursuant to which, the Employee is eligible for an incentive bonus payable upon the earlier of December 31, 2023 or closing of a Change of Control Transaction (as defined in the Retention Agreement) and to severance equal to six (6) months of her base salary in the event of a termination of her employment with the Company without cause;

 

WHEREAS, the Employee has been paid the Retention Bonus that she was entitled to receive under the Retention Agreement;

 

WHEREAS, the Parties desire to terminate the Retention Agreement; and

 

WHEREAS, the Employee and the Company desire to amend the Employment Agreement to reflect the Parties understanding regarding the Employee’s compensation under the Agreement.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

1. Amendment of Agreement.

 

A. Section 4(b) is hereby amended to add the following as a subsections (i), (ii) and (iii):

 

i. Transaction Bonus. The Employee shall be entitled to receive a transaction bonus in the amount of $25,000 (the “Transaction Bonus”) upon the closing of a Change in Control (as defined in Exhibit A), provided, the closing date of such Change in Control occurs no later than June 30, 2024, subject to, and conditioned upon, the Employee satisfying her obligations set forth in paragraph ii below. The Company will pay the Transaction Bonus, less applicable withholding, within sixty (60) days of the closing date of such Change in Control.

 

1
 

 

ii. Conditions to Earn Transaction Bonus. The Transaction Bonus shall only be earned and become payable if all of the following conditions are satisfied. If any of the conditions below are not satisfied, the Company shall have no obligation to pay the Transaction Bonus.

 

(A) The Employee must devote her time contributing to a successful completion of a Change in Control, including maximizing the Company’s operating and financial performance and value, working with financial advisors retained for purposes of the Change in Control, and use her best efforts to ensure the success of the Company during the pendency of any such potential Change in Control.

 

(B) The Change in Control must be consummated on or before June 30, 2024.

 

(C) The Employee must remain in continued employment with the Company through the closing date of the Change in Control and the payment date.

 

(D) The Employee must continue to comply with any restrictive covenants set forth in the Agreement or any other written agreement with the Company or its affiliate.

 

(E) The Employee executes (and does not revoke) a general release of claims to become effective as of the closing date of the Change in Control.

 

iii. Retention Bonus. The Employee shall be eligible to receive a retention bonus of $50,000 (“Retention Bonus”), which shall be paid no later than March 15th of the year following the year in which the Employee vests in the Retention Bonus. The Retention Bonus shall only be earned and become payable if all of the following conditions are satisfied. If any of the conditions below are not satisfied, the Company shall have no obligation to pay the Retention Bonus.

 

(A) The Employee must remain employed by the Company through the closing date of a subsequent Change in Control;

 

(B) The Employee must remain employed through the orderly wind-down and liquidation of the Company following such subsequent Change in Control; and

 

(C) if requested by the Compensation Committee of the Board (the “Committee”), the Employee enters into a suitable consulting agreement with the Company, if requested by the Company, following closing date of such subsequent Change in Control and does not breach any material term of such consulting agreement.”

 

2
 

 

B. Section 4(c)(iv) of the Agreement is hereby amended the following language to the end of the subsection:

 

“In the event that the Company terminates the Term and the Employee’s employment without Cause following a Change in Control, and the orderly wind-down and liquidation of the Company following such Change in Control, the Company shall pay or provide to the Employee, subject to paragraph vii below (other than with respect to Item (2)), and subject to applicable withholdings: (1) nine (9) months’ Base Salary (the “Severance Period”) and payment for continuation of group health benefits during the Severance Period (or, at the Board’s discretion, an equivalent amount as determined by the Board in good faith); and (2) the Employee’s Base Salary and Benefits accrued through the date of the Employee’s termination. Item (1) above, to the extent due, shall be paid in one lump sum within sixty (60) days of the Employee’s last day of employment with the Company. Upon payment to the Employee of the foregoing amounts, the Company shall have no further obligation or liability to or for the benefit of the Employee for duplicative payments or benefits under any other agreement, except as required by applicable law. Notwithstanding the foregoing, the Board, in its sole discretion, may pay any severance or the equivalent of the continuation of Benefits (as determined by the Board in good faith) payable pursuant to the Section 4(c)(iv) or (vi) in a lump sum to the extent permissible under Section 409A of the Code.”

 

2. Termination of Retention Agreement. The Parties hereby agree to terminate the Retention Agreement and acknowledge that the Employee is only entitled to severance under the Agreement and is not entitled to severance under the Retention Agreement.

 

3. Acknowledgement. The Employee acknowledges and agrees that by executing this Amendment, the Employee expressly consents to the changes to the terms and conditions in the Agreement.

 

4. Agreement Effective. Except as otherwise expressly provided herein, all terms and conditions of the Agreement will remain unmodified and in full force and effect.

 

5. Precedence of Amendment. In the event of a conflict between the terms and conditions of this Amendment and the terms and conditions of the Agreement, the terms and conditions of this Amendment will govern and control.

 

6. Capitalized Terms. All capitalized terms used in this Amendment and not otherwise defined herein will have the meaning ascribed to such terms in the Agreement.

 

7. Incorporation. This Amendment shall be attached to, and made a part of, the Agreement.

 

8. Counterparts. This Amendment may be executed in one or more copies or counterparts, each of which when signed will be an original, but all of which together will constitute one instrument. Signatures submitted via telecopy or electronic signature shall have the same force and effect as original signatures and, as such, shall be valid and binding upon the parties hereto.

 

[signature page follows]

 

3
 

 

In witness whereof, the Parties hereto have executed this Amendment as of the signature dates set forth below, to be effective as of the date hereof.

 

GUARDION HEALTH SCIENCES, INC.,   “EMPLOYEE”
a Delaware corporation      
         
By:     By:  
  Robert N. Weingarten     Katie Cox
         
Date:   Date:

 

4

 

 EX-10.3 4 ex10-3.htm

 

Exhibit 10.3

 

AMENDMENT

TO EMPLOYMENT AGREEMENT

 

This Amendment to Employment Agreement (this “Amendment”), dated effective as of the last date of signature noted on the signature page, is entered into by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), Craig Sheehan (the “Employee” and together with the Company, collectively, the “Parties”).

 

RECITALS

 

WHEREAS, the Employee and the Company are parties to that certain Employment Agreement, effective as of June 2, 2021 (the “Employment Agreement”), pursuant to which, among other things, the Employee serves as the Chief Commercial Officer; and

 

WHEREAS, the Employee and the Company desire to amend the Employment Agreement to reflect the Parties understanding regarding the Employee’s compensation.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

AGREEMENT:

 

1. Amendment of Agreement.

 

Section 5(c)(iv) of the Agreement is hereby amended to add the following language to the end of the subclause:

 

“In the event that the Company terminates the Term and the Employee’s employment without Cause following a Change in Control (as defined in the Incentive Plan) that is consummated on or before June 30, 2024, the Company shall pay the Employee, subject to paragraph vii below and subject to applicable withholdings a retention bonus in the amount of $35,000 (the “Retention Bonus”) in one lump sum within sixty (60) days of the Employee’s last day of employment with the Company. In the event a Change in Control is not consummated on or before June 30, 2024, the Employee shall not be entitled to the Retention Bonus. Notwithstanding the foregoing, the Board, in its sole discretion, may pay any severance and continuation of group health benefits during the severance period (or, at the Board’s discretion, an equivalent amount as determined by the Board in good faith) payable pursuant to Section 5(c)(iv) or (vi) in a lump sum to the extent permissible under Section 409A of the Code; provided, however, in the event that within 90 days following the termination of the Employee’s employment by the Company without Cause or by the Employee for Good Reason upon or following the consummation of a Change in Control that occurs on or before June 30, 2024, the Employee becomes engaged or retained, as an employee, consultant, independent contractor, advisor, or otherwise, on a full-time basis by acquiror or an affiliate of the acquiror in such Change of Control, the Employee will be required to repay the Company the full severance amount paid to Employee, plus, if Employee fails to timely repay the Company such severance, any fees or expenses incurred by the Company to collect such severance payments. For purposes of the prior sentence, to be engaged or retained on a “full-time basis” shall mean working an average of 40 hours per week.”

 

1
 

 

2. Acknowledgement. The Employee acknowledges and agrees that by executing this Amendment, the Employee expressly consents to the changes to the terms and conditions in the Agreement.

 

3. Agreement Effective. Except as otherwise expressly provided herein, all terms and conditions of the Agreement will remain unmodified and in full force and effect.

 

4. Precedence of Amendment. In the event of a conflict between the terms and conditions of this Amendment and the terms and conditions of the Agreement, the terms and conditions of this Amendment will govern and control.

 

5. Capitalized Terms. All capitalized terms used in this Amendment and not otherwise defined herein will have the meaning ascribed to such terms in the Agreement.

 

6. Incorporation. This Amendment shall be attached to, and made a part of, the Agreement.

 

7. Counterparts. This Amendment may be executed in one or more copies or counterparts, each of which when signed will be an original, but all of which together will constitute one instrument. Signatures submitted via telecopy or electronic signature shall have the same force and effect as original signatures and, as such, shall be valid and binding upon the parties hereto.

 

[signature page follows]

 

2
 

 

In witness whereof, the Parties hereto have executed this Amendment as of the signature dates set forth below, to be effective as of the date hereof.

 

GUARDION HEALTH SCIENCES, INC.,     “EMPLOYEE” 
a Delaware corporation      
         
By:     By:  
  Robert N. Weingarten     Craig Sheehan
         
Date:     Date:  

 

3

 

 EX-101.SCH 5 ghsi-20240403.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 ghsi-20240403_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ghsi-20240403_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 03, 2024
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ghsi-20240403.xsd ghsi-20240403_lab.xml ghsi-20240403_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20240403", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ghsi-20240403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ghsi-20240403_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20240403_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://guardionhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-014076-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014076-xbrl.zip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end XML 19 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2024-04-03 2024-04-03 iso4217:USD shares iso4217:USD shares false 0001642375 8-K 2024-04-03 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per share GHSI NASDAQ true false